Business Description
HLS Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA40390B1094
Compare
Compare
Traded in other countries / regions
HLS.CanadaHLTRF.USA74D.Germany IPO Date
1959-04-22Description
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.24 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.89 | |||||
| Debt-to-EBITDA | 7.13 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -0.61 | |||||
| Beneish M-Score | -3.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2 | |||||
| 3-Year EBITDA Growth Rate | -5.2 | |||||
| 3-Year EPS without NRI Growth Rate | -19.5 | |||||
| 3-Year FCF Growth Rate | -16.9 | |||||
| 3-Year Book Growth Rate | -11.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.76 | |||||
| 9-Day RSI | 42.24 | |||||
| 14-Day RSI | 38.69 | |||||
| 6-1 Month Momentum % | 15.12 | |||||
| 12-1 Month Momentum % | -51.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.72 | |||||
| Quick Ratio | 1.37 | |||||
| Cash Ratio | 0.86 | |||||
| Days Inventory | 533.67 | |||||
| Days Sales Outstanding | 53.17 | |||||
| Days Payable | 704.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.17 | |||||
| 3-Year Dividend Growth Rate | 1.5 | |||||
| Forward Dividend Yield % | 5.56 | |||||
| 5-Year Yield-on-Cost % | 4.17 | |||||
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | 2.66 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.5 | |||||
| Operating Margin % | -21.25 | |||||
| Net Margin % | -45.34 | |||||
| FCF Margin % | 24.78 | |||||
| ROE % | -24.26 | |||||
| ROA % | -12.23 | |||||
| ROIC % | -6.43 | |||||
| ROC (Joel Greenblatt) % | -426.09 | |||||
| ROCE % | -10.27 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.37 | |||||
| PB Ratio | 0.84 | |||||
| Price-to-Free-Cash-Flow | 5.53 | |||||
| Price-to-Operating-Cash-Flow | 5.52 | |||||
| EV-to-EBIT | -7.41 | |||||
| EV-to-EBITDA | 12.13 | |||||
| EV-to-Revenue | 2.45 | |||||
| EV-to-Forward-Revenue | 2.27 | |||||
| EV-to-FCF | 9.67 | |||||
| Price-to-Projected-FCF | 0.43 | |||||
| Earnings Yield (Greenblatt) % | -13.5 | |||||
| FCF Yield % | 18.24 | |||||
| Forward Rate of Return (Yacktman) % | -6.99 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HLS Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 84.998 | ||
| EPS (TTM) (C$) | -1.187 | ||
| Beta | 1.14 | ||
| Volatility % | 67.26 | ||
| 14-Day RSI | 38.69 | ||
| 14-Day ATR (C$) | 0.214761 | ||
| 20-Day SMA (C$) | 3.8065 | ||
| 12-1 Month Momentum % | -51.23 | ||
| 52-Week Range (C$) | 3.34 - 11.22 | ||
| Shares Outstanding (Mil) | 32.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HLS Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HLS Therapeutics Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
HLS Therapeutics Inc Frequently Asked Questions
What is HLS Therapeutics Inc(TSX:HLS)'s stock price today?
The current price of TSX:HLS is C$3.60. The 52 week high of TSX:HLS is C$11.22 and 52 week low is C$3.34.
When is next earnings date of HLS Therapeutics Inc(TSX:HLS)?
The next earnings date of HLS Therapeutics Inc(TSX:HLS) is .
Does HLS Therapeutics Inc(TSX:HLS) pay dividends? If so, how much?
The Dividend Yield %  of HLS Therapeutics Inc(TSX:HLS) is 4.17% (As of Today), Highest Dividend Payout Ratio of HLS Therapeutics Inc(TSX:HLS) was 0.48. The lowest was 0. And the median was 0.36. The  Forward Dividend Yield % of HLS Therapeutics Inc(TSX:HLS) is 5.56%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers